Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a pooled analysis of 96 recurrent grade III ma...

詳細記述

保存先:
書誌詳細
主要な著者: Reardon, David A., Herndon, James E., Peters, Katherine, Desjardins, Annick, Coan, April, Lou, Emil, Sumrall, Ashley, Turner, Scott, Sathornsumetee, Sith, Rich, Jeremy N., Boulton, Susan, Lipp, Eric S., Friedman, Henry S., Vredenburgh, James J.
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3403724/
https://ncbi.nlm.nih.gov/pubmed/21997879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0740-0
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料